Myriad Genetics Q2 Profit Soars 57%, Announces Acquisition

Myriad Genetics delivers 37% top-line growth and boosts its full-year forecast after announcing the acquisition of Crescendo Bioscience.

Feb 4, 2014 at 6:02PM

Following a number of tumultuous months, shareholders of molecular diagnostics company Myriad Genetics (NASDAQ:MYGN) have a reason to smile after the company delivered impressive second-quarter earnings results after the bell.

For the quarter, Myriad Genetics reported a 37% increase in revenue to $204.1 million as adjusted EPS increased a whopping 57% to $0.66.

Molecular diagnostics growth accounted for the bulk of Myriad's gains, with its oncology segment seeing sales increase 12% to $101.6 million and its women's health revenue soaring 90% to $94.6 million.

The company's BRACAnalysis test, a genetic test targeting the BRCA1 and BRCA 2 genes which are associated with a higher risk of breast and ovarian cancer, saw sales increase 28% to $141.2 million, and represented 69% of total company revenue. Similarly, the company's BART diagnostic also saw revenue rise 57% to $24.7 million.

Another bright spot for Myriad was the recent launch of its myRisk Hereditary Cancer Test which launch in September and brought in $11.5 million in revenue for the quarter.

Also after the bell, Myriad announced the acquisition of privately held Crescendo Bioscience for $270 million in cash (which will be reduced by $25 million for the repayment of a loan made to Crescendo). Crescendo's diagnostics portfolio and focus on the rheumatoid arthritis market will "enable us to move to the next level in terms of scale and growth," according to William Hagstrom, CEO of Crescendo Bioscience.

Looking ahead, and factoring in its acquisition of Crescendo, Myriad Genetics boosted its full-year 2014 revenue and EPS guidance to a new range of $740 million to $750 million and $2.09-$2.12 from its own prior forecast of $700 million to $715 million and $1.92-$1.97.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information